It depends on whether you value the new drug pipeline. If you make it unprofitable to develop new drugs, new drugs won't be developed.New drugs can still be developed if all consumers share the cost of the R&D--why should Americans shoulder almost all the burden, since everyone gains?Could it be that we're shouldering the burden because outside the U.S. the pharmys have to compete pricewise (heaven forbid), but here in the U.S. they can charge whatever they darn please?(And maybe it wouldn't hurt those pharmy CEOs/executives to take some compensation reductions either)2old
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.